{
    "clinical_study": {
        "@rank": "102461", 
        "acronym": "PARF2008", 
        "arm_group": {
            "arm_group_label": "Radiofrequency ablathermy", 
            "arm_group_type": "Experimental", 
            "description": "Radiofrequency ablathermy"
        }, 
        "brief_summary": {
            "textblock": "Lung tumors of non-small cell stage 1A are usually treated surgically but many patients are\n      not operable because of their condition or respiratory problems associated with it. The\n      treatment is then suggested that local radiotherapy is conventionally carried out in split\n      mode for 6 weeks at a dose of 60-65 Gy irradiation mode This exposes the patient to\n      complications, including post-radiation pneumonitis."
        }, 
        "brief_title": "Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Malignant Non-small Cell Neoplasm of Lung Stage Ia", 
        "condition_browse": {
            "mesh_term": [
                "Bronchial Neoplasms", 
                "Neoplasms", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Lung tumors of non-small cell stage 1A are usually treated surgically but many patients are\n      not operable because of their condition or respiratory problems associated with it.\n\n      The treatment is then suggested that local radiotherapy is conventionally carried out in\n      split mode for 6 weeks at a dose of 60-65 Gy irradiation mode This exposes the patient to\n      complications, including post-radiation pneumonitis.\n\n      This can be problematic in patients with respiratory failure for which surgical treatment\n      has been challenged. Radiofrequency pulmonary developed as a therapeutic alternative, it has\n      the advantage of being performed in a session with less toxicity in the lung parenchyma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          1. Patients over 18 years\n\n          2. Histological diagnosis of non-small cell lung tumor established.\n\n          3. Stage 1A tumors (lesions <= 3 cm, N0) report prepared by PET and CT\n\n          4. Surgical treatment of the lesion contrindiqu\u00e9 or refused by the patient,\n\n          5. ARF considered technically feasible after discussing the case in a multidisciplinary\n             meeting (RCP)\n\n          6. Expectancy greater than 6 months life\n\n          7. PET before inclusion (8 weeks maximum before radiofrequency) showing uptake (SUV> =\n             2.5) at the lesion to be treated,\n\n          8. Signed informed consent,\n\n          9. Patient affiliated to a social security scheme.\n\n        Exclusion criteria :\n\n          1. Location of the lesion does not allow achieving ablathermy under satisfactory\n             conditions: lesion contiguous to the major anatomical structures of the mediastinum,\n             hilar location (less than 1 cm from the hilum)\n\n          2. Disorder of uncontrolled bleeding (TP <50% TCA> 1.5 x control).\n\n          3. Abnormal blood count platelets <90000/mm3\n\n          4. Cons-indication to general anesthesia\n\n          5. Patient with a cardiac pacemaker if a review indicates treatment against ARF\n\n          6. pregnancy\n\n          7. Patient included in another clinical study\n\n          8. Unable to undergo medical monitoring test for geographical, social or psychological\n             reasons,\n\n          9. Private patient freedom and major subject of a measure of legal protection or unable\n             to consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841060", 
            "org_study_id": "IB2008-34"
        }, 
        "intervention": {
            "arm_group_label": "Radiofrequency ablathermy", 
            "description": "Radiofrequency", 
            "intervention_name": "Radiofrequency", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Malignant Non-small Cell Neoplasm of Lung", 
        "lastchanged_date": "April 23, 2013", 
        "link": {
            "description": "Institut Bergonie", 
            "url": "http://www.bergonie.org/fr/essais-clinique.html"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "CHU de Bordeaux"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75970"
                    }, 
                    "name": "H\u00f4pital de Tenon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75908"
                    }, 
                    "name": "H\u00f4pital Europ\u00e9en Georges Pompidou"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75000"
                    }, 
                    "name": "H\u00f4pital Cochin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pau", 
                        "country": "France", 
                        "zip": "64000"
                    }, 
                    "name": "CH de Pau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU de Rennes"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67091"
                    }, 
                    "name": "CHU de Strasbourg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU Rangueil-Larrey"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94800"
                    }, 
                    "name": "Institut Gustave Roussy"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Assessment of the Effectiveness of Local Ablathermy Radio Frequency (RF) Bronchial Tumors Primitive Stage IA Non-surgical Patients. Phase II Multicenter National", 
        "other_outcome": {
            "description": "Evaluation of the duration of hospitalization, Performance Evaluation of the PET in the diagnosis of tumor progression", 
            "measure": "Evaluation of the duration of hospitalization, Performance Evaluation of the PET in the diagnosis of tumor progression", 
            "safety_issue": "No", 
            "time_frame": "07/2011 (1 and 3 years)"
        }, 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9", 
            "last_name": "Jean PALUSSIERE, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluation of the effectiveness of local ablathermy radiofrequency (RF) lung tumors primitive stage IA non-surgical patients. The effectiveness will be evaluated in terms of local control rate at 1 year", 
            "measure": "Evaluation of the effectiveness of local ablathermy radiofrequency (RF) lung tumors primitive stage IA non-surgical patients. The effectiveness will be evaluated in terms of local control rate at 1 year", 
            "safety_issue": "No", 
            "time_frame": "07/2011 (1 year)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841060"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tEvaluation of overall survival at 1 and 3 years Bookseller local control rates at 3 years, Evaluation of respiratory function before and after treatment, Assessment of quality of life before and after treatment, Evaluation of tolerance to treatment: side effects and complications associated with the technique, Evaluation of the duration of hospitalization, Performance Evaluation of the PET in the diagnosis of tumor progression", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "07/2011 (1 and 3 years)"
            }, 
            {
                "description": "Evaluation of overall survival at 1 and 3 years, the local control rates at 3 years, lung function before and after treatment, quality of life before and after treatment, the tolerability", 
                "measure": "Evaluation of overall survival at 1 and 3 years, the local control rates at 3 years, lung function before and after treatment, quality of life before and after treatment, the tolerability", 
                "safety_issue": "No", 
                "time_frame": "07/2011 (1 and 3 years)"
            }
        ], 
        "source": "Institut Bergoni\u00e9", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, France", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Institut Bergoni\u00e9", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2008", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}